ArticleScientific reports2021
Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin's lymphoma.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Evaluation of Baseline and Interim-Therapy PET Features for Prognostication in High-Risk Pediatric Hodgkin Lymphoma: A Retrospective Analysis of the AHOD1331 Trial.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Role ofTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Is Baseline PET/CT-Derived Metabolic Tumor Burden Associated with Treatment Response and Survival in Hodgkin Lymphoma?Journal of clinical medicine · 2026Article
- Prognostic Value of Massiveness Parameters Measured on Baseline FDG PET in Advanced-Stage Hodgkin Lymphoma.Cancer medicine · 2025Article
- Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials.Blood cancer journal · 2025Article
- Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma.Scientific reports · 2024Article
- Advances in positron emission tomography and radiomics.Hematological oncology · 2023Review
- Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study.British journal of haematology · 2023Article
- Liquid biopsy in hematological malignancies: current and future applications.Frontiers in oncology · 2023Review
- Repeatability of metabolic tumor burden and lesion glycolysis between clinical readers.Frontiers in immunology · 2023Article
- Volumetric parameters from [Journal of neuroendocrinology · 2022Observational
- Healthy Organs Uptake on BaselineFrontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our aim was to evaluate the prognostic value of initial total metabolic tumour volume (TMTV) in a population of patients with advanced-stage Hodgkin's lymphoma (HL). We retrospectively included 179 patients with stage IIb-III-IV Hodgkin's disease who received BEACOPP or ABVD as the first-line treatment. The initial TMTV was determined using a semi-automatic method for each patient. We analysed its prognostic value in terms of 5-year progression-free survival (PFS), overall survival, and positron emission tomography (PET) response after two courses of chemotherapy. Considering all the treatments and using a threshold of 217 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.